Teva Pharmaceutical Industries Limited — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · Israel
Last price 41.47 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 48.32B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Details
| Name | Teva Pharmaceutical Industries Limited |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 33950 |
| Founded | 1901 |
| Ceo | Richard Francis |
| Country | Israel |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | IL0006290147 |
| Cik | 0000818686 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Richard D. Francis | President, Chief Executive Officer and Director |
| Eliyahu Sharon Kalif | Executive Vice President and Chief Financial Officer |
| Dr. Eric A. Hughes M.D., Ph.D. | Executive Vice President of Global Research & Development and Chief Medical Officer |
| Christine Fox | Executive Vice President of US Commercial and Head of Innovative Franchise |
| Evan Lippman M.B.A. | Executive Vice President of Business Development |
| Matthew Shields | Executive Vice President of Global Operations |
| Amir Weiss | Senior Vice President and Chief Accounting Officer |
| Christopher J. Stevo CFA | Senior Vice President of Investor Relations and Competitive Intelligence |
| Kathleen Veit | Senior Vice President, Global Compliance and Ethics Officer |
| Brian Savage | Interim Chief Legal Officer |
Contact
| Address | 124 Dvora HaNevi’a St., Tel Aviv-Yafo, 6944020, Israel |
| Phone | 972 3 914 8213 |
| Website | https://www.tevapharm.com |